Laux DE - Search Results

1

High-specific-activity ¹³¹iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma.

Dillon JS, Bushnell D, Laux DE. Dillon JS, et al. Among authors: laux de. Future Oncol. 2021 Apr;17(10):1131-1141. doi: 10.2217/fon-2020-0625. Epub 2021 Jan 28. Future Oncol. 2021. PMID: 33506713 Free PMC article.

2

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).

Xia C, Leon-Ferre R, Laux D, Deutsch J, Smith BJ, Frees M, Milhem M. Xia C, et al. Cancer Chemother Pharmacol. 2014 Oct;74(4):691-7. doi: 10.1007/s00280-014-2501-1. Epub 2014 Jul 26. Cancer Chemother Pharmacol. 2014. PMID: 25062770 Free PMC article. Clinical Trial.

3

Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC).

Furqan M, Snyders TP, Saqlain MU, Mott SL, Laux D, Snow A, Anderson CM, Watkins JM, Clamon GH. Furqan M, et al. Cancer Med. 2019 Jun;8(6):2730-2739. doi: 10.1002/cam4.2139. Epub 2019 Apr 9. Cancer Med. 2019. PMID: 30968604 Free PMC article.

4

A pathogenic germline BRCA2 variant in a patient with hypopharyngeal squamous cell carcinoma.

Correa T, Laux DE, Hoffman HT. Correa T, et al. Among authors: laux de. Clin Case Rep. 2020 Nov 25;9(1):429-432. doi: 10.1002/ccr3.3548. eCollection 2021 Jan. Clin Case Rep. 2020. PMID: 33489192 Free PMC article.

5

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.

Espinosa-Cotton M, Rodman Iii SN, Ross KA, Jensen IJ, Sangodeyi-Miller K, McLaren AJ, Dahl RA, Gibson-Corley KN, Koch AT, Fu YX, Badovinac VP, Laux D, Narasimhan B, Simons AL. Espinosa-Cotton M, et al. J Immunother Cancer. 2019 Mar 19;7(1):79. doi: 10.1186/s40425-019-0550-z. J Immunother Cancer. 2019. PMID: 30890189 Free PMC article.

6

Time to put it out - nurse-facilitated tobacco treatment in a comprehensive cancer center.

Katz DA, Mott SL, Utech JA, Bahlmann AC, Dukes KA, Seaman AT, Laux DE, Furqan M, Pollock ZJ, Vander Weg MW. Katz DA, et al. Among authors: laux de. Transl Behav Med. 2021 Sep 15;11(9):1726-1738. doi: 10.1093/tbm/ibab073. Transl Behav Med. 2021. PMID: 34347876 Free PMC article.

7

Corrigendum to: Time to put it out - nurse-facilitated tobacco treatment in a comprehensive cancer center.

Katz DA, Mott SL, Utech JA, Bahlmann AC, Dukes KA, Seaman AT, Laux DE, Furqan M, Pollock ZJ, Vander Weg MW. Katz DA, et al. Among authors: laux de. Transl Behav Med. 2022 Mar 17;12(3):498. doi: 10.1093/tbm/ibab149. Transl Behav Med. 2022. PMID: 34865161 Free PMC article. No abstract available.

8

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.

9

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers.

Kolesar JM, Andrews S, Green H, Havighurst TC, Wollmer BW, DeShong K, Laux DE, Krontiras H, Muccio DD, Kim K, Grubbs CJ, House MG, Parnes HL, Heckman-Stoddard BM, Bailey HH. Kolesar JM, et al. Among authors: laux de. Cancer Prev Res (Phila). 2019 Dec;12(12):903-912. doi: 10.1158/1940-6207.CAPR-19-0310. Epub 2019 Sep 4. Cancer Prev Res (Phila). 2019. PMID: 31484659 Free PMC article. Clinical Trial.

10

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.

Espinosa-Cotton M, Fertig EJ, Stabile LP, Gaither-Davis A, Bauman JE, Schmitz S, Gibson-Corley KN, Cheng Y, Jensen IJ, Badovinac VP, Laux D, Simons AL. Espinosa-Cotton M, et al. Biomark Res. 2019 Jul 16;7:14. doi: 10.1186/s40364-019-0164-0. eCollection 2019. Biomark Res. 2019. PMID: 31346466 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters